Sheikhhasani Shahrzad, Moosavi Azam Sadat, Akhavan Setareh, Zamani Narges, Rezayof Elahe, Mosavat Mina Sadat
Department of Gynecology Oncology, Tehran University of Medical Sciences, Valie-E-Asr Hospital, Tehran, Iran.
Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ann Med Surg (Lond). 2025 Apr 15;87(6):3107-3112. doi: 10.1097/MS9.0000000000003297. eCollection 2025 Jun.
This study aimed to analyze clinical characteristics, recurrence patterns, and survival predictors in patients with recurrent epithelial ovarian cancer.
We conducted a retrospective analysis of 284 patients with recurrent epithelial ovarian cancer treated at our institution between 2012 and 2022. Clinical data, recurrence patterns, treatment modalities, and survival outcomes were evaluated. Kaplan-Meier analysis and Cox proportional hazards models were used to assess survival and identify prognostic factors.
The mean age at recurrence was 54.47 years. Multiple site recurrence (50.70%) was the most common, followed by peritoneal (21.47%) and distant metastases (15.84%). Median progression-free survival (PFS) and overall survival (OS) were 5.00 and 23.00 months, respectively. Retroperitoneal recurrence was associated with better survival compared to distant recurrence (median OS 29.00 vs 16.00 months, = 0.007). Multivariate analysis identified residual disease (HR 2.15, < 0.001), elevated CA-125 (HR 1.6, = 0.02), high-grade histology (HR 1.5, = 0.01), and advanced initial stage (HR 1.7, = 0.002) as significant predictors of poor survival.
Recurrence patterns and timing significantly impact survival in recurrent ovarian cancer. Complete cytoreduction, tumor grade, and initial stage are crucial prognostic factors. These findings emphasize the need for personalized treatment strategies and continued research into novel therapeutic approaches.
本研究旨在分析复发性上皮性卵巢癌患者的临床特征、复发模式和生存预测因素。
我们对2012年至2022年在我院接受治疗的284例复发性上皮性卵巢癌患者进行了回顾性分析。评估了临床数据、复发模式、治疗方式和生存结果。采用Kaplan-Meier分析和Cox比例风险模型评估生存情况并确定预后因素。
复发时的平均年龄为54.47岁。多部位复发（50.70%）最为常见，其次是腹膜复发（21.47%）和远处转移（15.84%）。中位无进展生存期（PFS）和总生存期（OS）分别为5.00个月和23.00个月。与远处复发相比，腹膜后复发患者的生存情况更好（中位OS为29.00个月对16.00个月，P = 0.007）。多因素分析确定残留病灶（HR 2.15，P < 0.001）、CA-125升高（HR 1.6，P = 0.02）、高级别组织学类型（HR 1.5，P = 0.01）和晚期初始分期（HR 1.7，P = 0.002）是生存不良的重要预测因素。
复发模式和时间对复发性卵巢癌的生存有显著影响。完全细胞减灭术、肿瘤分级和初始分期是关键的预后因素。这些发现强调了个性化治疗策略的必要性以及对新型治疗方法持续研究的重要性。
